⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RIGL News
Rigel Pharmaceuticals Inc. (New)
Form 8-K
sec.gov
RIGL
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
prnewswire.com
RIGL
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
globenewswire.com
FHTX
CRNX
RIGL
Rigel Appoints Michael P. Miller to the Board of Directors
prnewswire.com
RIGL
Zapata Secures Foundational Patent for Interoperable Quantum Software Across Key Global Markets
globenewswire.com
MSFT
NVDA
RIGL
RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
prnewswire.com
MRK
LLY
RIGL
AZN
GILD
ABBV
PFE
TMO
BMY
NVS
BIIB
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight
globenewswire.com
JNJ
BIIB
NVS
VTRS
RPRX
ABBV
AZN
MRK
RIGL
GSK
REGN
GILD
AMGN
LLY
BMY
XBI
IBB
Rigel Provides Business Update and 2026 Outlook
prnewswire.com
RIGL
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com
RIGL
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio
globenewswire.com
RIGL